Original Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 7, 2009; 15(21): 2587-2594
Published online Jun 7, 2009. doi: 10.3748/wjg.15.2587
Table 4 Time-related changes by period analysis n (%)
First period (Jan 1994-Jan 2000)Second period (Feb 2000-Jan 2006)P
Patients (male:female)93 (63:30)143 (90:53)NS
Age (yr) (mean, range)63.9 (40-81)62.5 (36-81)NS
1-yr survival rate88.3%85.6%NS
1-yr recurrence rate38.5%44%NS
Anesthetic risk
ASA I-II60 (64.5)90 (62.9)NS
ASA III-IV33 (35.5)53 (37.1)NS
Number nodules1.77 (1-6)2.3 (1-11)0.012
Size of nodules3.8 (0.8-11)3 (0.2-12)NS
Bilobar disease19 (20.4)57 (39.9)0.002
Extrahepatic disease1 (1.1) 10 (7)0.03
Preoperative CEA level (ng/dL)13.5 (0.4-3203)8.9 (0.6-1715)0.03
Adjuvant treatment to CLM13 (14)49 (34.3)0.001
Resectability rate69.9%86.7%0.002
Use of intraoperative US91.3%92.9%NS
Concordance of IOUS56.5%67.9%NS
Procedures performed0.024
Major hepatectomy23 (35.4)28 (22.6)
Minor hepatectomy18 (27.7)48 (38.7)
Atypical hepatectomy17 (26.2)20 (16.1)
Combined hepatectomy7 (10.8)28 (22.6)
Operative time (min)226.7 ± 58.8251 ± 65.30.01
Blood loss (mL)440 (25-1700)560 (80-2500)NS
Need of transfusion40%44.7%NS
Complications rate32.3%60.5%0.001
Minor complications24.6%54%0.001
Major complications7.7%5.6%NS
Postoperative stay (d)11 (5-34)9 (4-43)0.018
Postoperative mortality1.5%1.6%NS
Complementary treatment of CLM60%49.2%NS